Abstract
In recent years, immunoadsorption has become an increasingly recognized alternative to therapeutic plasmapheresis used totreat neurological diseases, such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myastheniagravis, neuromyelitis optica and its spectrum disorders, multiple sclerosis, or autoimmune encephalitides. In contrast to therapeuticplasmapheresis that requires plasma exchange with albumin or fresh-frozen plasma, immunoadsorption is a technique allowingselective removal of humoral factors, primarily of pathological autoantibodies, with a high-affinity adsorbent.
This therapeuticmethod has fewer adverse effects when compared with plasmapheresis. It can significantly improve the treatment and prognosisof patients with autoimmune neurological disorders.